Young Marijuana Users Respond Differently to Social Exclusion
Philadelphia, PA March 2, 2016
A new study published in the current issue of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging reports that young adults who regularly use marijuana display altered brain activation patterns during social exclusion.
“Peer groups are one of the most important predictors of young adult marijuana use, and yet we know very little about the neural correlates of social rejection in those who use marijuana,” explained Dr. Jodi Gilman, first author and Assistant Professor at Harvard Medical School.
This led Gilman and her colleagues to conduct a neuroimaging study using a Cyberball task, where participants played a computerized game of catch while undergoing a non-invasive brain scan. They recruited 42 young adults (ages 18-25), about half of whom regularly used marijuana. Unknown to the study participants, the other ‘players’ in the game were computers and were programmed to exclude them for a portion of the game.
The non-using subjects demonstrated activation in the right anterior insula, a region associated with negative emotion and social rejection, when being excluded from the game, but the marijuana-using subjects did not. All subjects showed activation of ventral anterior cingulate cortex, a region associated with emotional monitoring, during peer exclusion, which correlated with measures of peer conformity and suggestibility.
“In this study, during peer rejection, young adult marijuana users had reduced activation in the insula, a brain region usually active during social rejection,” said Gilman. “This may reflect impaired processing of social information in marijuana users. Reduced activity in the insula to peer rejection could indicate that marijuana users are less conscious of social norms, or have reduced capacity to reflect on or react to negative social situations.”
“The results suggest that the cannabis users are less sensitive to exclusion than non-drug using individuals,” added Dr. Cameron Carter, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. “The study does not address whether this impaired processing is a core trait of cannabis users or a byproduct of the drug use itself.”
Therefore, more research is still necessary, including longitudinal designs to assess the developmental trajectory of this altered social processing and determine whether impaired processing of social exclusion is caused by, is a result of, or develops along with marijuana use.
The article is “Altered Neural Processing to Social Exclusion in Young Adult Marijuana Users” by Jodi M. Gilman, Max T. Curran, Vanessa Calderon, Randi M. Schuster, and A. Eden Evins (doi: 10.1016/j.bpsc.2015.11.002). The article appears in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, Volume 1, Issue 2 (March 2016), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or BPCNNI@utsouthwestern.edu. Journalists wishing to interview the authors may contact Dr. Jodi Gilman at +1 617 643 7293 or firstname.lastname@example.org.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
Cameron S. Carter, M.D. is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is an official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Editorial Office, Biological Psychiatry
+1 214 648 0880